Figure A11.
Kaplan-Meier curves for microvascular outcome Neuro-1 (score of >2.0 on the Michigan Neuropathy Screening Instrument) by glycemia arm. Panel A: data until transition of intensive glycemia arm to standard therapy. Panel B: all data through end of study. Hazard ratios adjusted for baseline history of clinical cardiovascular disease and second trial treatment arm assignment.